MAPT and Alzheimer disease: Additionally, the ultrastructural differences between AD NFTs and those of other tauopathies and how these contribute to disease onset and progression [92] all are critical considerations more amenable to preclinical mechanistic studies and could facilitate the development of more efficient prevention trials targeting tau.